ResMed, Inc.

Equities

Market Closed - Nyse Other stock markets 21:00:03 15/05/2026 BST			5-day change	1st Jan Change
201.88 ^USD	-0.29%		-2.36%	-16.19%

05-11	Resmed Insider Sold Shares Worth $1,037,233, According to a Recent SEC Filing	MT
05-04	CSL, Resmed, Cochlear Lead Losses on ASX	MT

Published on 10/30/2025 at 10:50 pm GMT - Modified on 11/07/2025 at 03:23 am GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin. I'll be your operator for today's call. [Operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

05-11	Resmed Insider Sold Shares Worth $1,037,233, According to a Recent SEC Filing	MT
05-04	CSL, Resmed, Cochlear Lead Losses on ASX	MT
05-02	ResMed: Stock splutters, but machine is still breathing well
05-01	Mizuho Securities Adjusts ResMed Price Target to $235 From $255, Maintains Outperform Rating	MT
05-01	Piper Sandler Adjusts ResMed Price Target to $233 From $275, Maintains Neutral Rating	MT
05-01	RBC Raises Price Target on ResMed to $321 From $314, Keeps Outperform Rating	MT
05-01	Stifel Nicolaus Adjusts ResMed Price Target to $235 From $265	MT
05-01	Jefferies Adjusts ResMed Price Target to $240 From $290	MT
05-01	Wells Fargo Adjusts ResMed Price Target to $227 From $270	MT
05-01	Baird Adjusts ResMed Price Target to $225 From $254	MT
05-01	ResMed: Stock coughs, but the machine is still breathing well
05-01	ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue; Shares Hit Over Two-Year Low	MT
05-01	Daily Special: Sierra Nevada Gold, LTR Pharma, NH3 Clean Energy	FI
05-01	ASX Preview: Australian Shares Set to Rise as Oil Prices Ease; ANZ Group Holdings Posts Higher Fiscal H1 Cash Earnings, Operating Income	MT
05-01	ResMed beats quarterly profit estimates, names new CFO	RE